https://www.selleckchem.com/pr....oducts/LY2784544.htm
We aimed to calculate cumulative hepatitis C virus (HCV) treatment coverage among individuals enrolled in opioid agonist therapy (OAT) in Norway between 2013 and 2017 and to document the treatment transition to direct-acting antiviral (DAA) agents. Moreover, we aimed to describe adherence to DAAs in the same cohort. Prospective cohort, registry data. Specialist healthcare service (secondary) PARTICIPANTS AND OUTCOMES This observational study was based on data from The Norwegian Prescription Database. We studied dispensed OAT and HCV t
Like
Comment
Share
